Sign in
DJA

Danielle Joy Antalffy

Managing Director and Senior Equity Analyst at UBS Asset Management Americas Inc.

New York, New York, United States

Danielle Joy Antalffy is a Managing Director and Senior Equity Analyst at UBS Investment Bank specializing in healthcare and medical technology, with an emphasis on the coverage of companies such as Tandem Diabetes Care, Senseonics Holdings, Dexcom, Insulet, and Edwards Lifesciences. Over her career, she has issued more than 700 stock ratings, maintaining a 50–52% success rate and generating average returns of 2.7–5.8%, with standout calls such as a 469% return on Senseonics Holdings. Antalffy joined UBS in 2022 after serving as Managing Director at Leerink Partners (2008–2022) and holding earlier analyst roles at Bear Stearns and Janney Montgomery Scott, following her undergraduate studies at the University of Pennsylvania. She holds professional credentials including registration with FINRA and relevant securities licenses, earning recognition for consistent performance and sector expertise.

Danielle Joy Antalffy's questions to ABBOTT LABORATORIES (ABT) leadership

Question · Q3 2025

Danielle Joy Antalffy questioned Abbott's strategy and evolution in Left Atrial Appendage (LAA) closure within structural heart, particularly regarding concomitant procedures and the outlook for 2026 and beyond. She also asked about the barriers preventing faster CGM penetration in the U.S. basal segment, which remains at 20%.

Answer

Chairman and CEO Robert Ford acknowledged the need to improve LAA share in concomitant procedures, highlighting positive physician feedback on their next-generation Amulet device, with trial enrollment complete and filing expected in H1 2026 for a potential 2026/2027 launch. For CGM, he attributed slower U.S. basal penetration to the large universe of primary care physicians needing coverage and awareness, emphasizing Abbott's efforts in sales force expansion, sampling, and Epic integration.

Ask follow-up questions

Fintool

Fintool can predict ABBOTT LABORATORIES logo ABT's earnings beat/miss a week before the call

Let Fintool AI Agent track Danielle Joy Antalffy for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free